| Catalog No. | Size | Price (USD) |
| 51048-R017-1 | 1 mL | $1,969.87 |
| 51048-R017-20 | 20 µL | $118.49 |
| 51048-R017-50 | 50 µL | $177.58 |
| 51048-R017-100 | 100 µL | $340.51 |
General Information
| Product name | Recombinant Anti-GM-CSF/CSF2 Antibody, Rabbit Monoclonal |
| Validated applications | ELISA (FAQ Protocol), ELISA(Cap) (FAQ Protocol) |
| Species reactivity | Reacts with: Mouse |
| Specificity | Mouse GM-CSF/CSF2 |
| Immunogen | Recombinant Mouse GM-CSF/CSF2 Protein (Catalog#51048-M07H) |
| Preparation | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse GM-CSF/CSF2 (rM GM-CSF/CSF2; Catalog#51048-M07H; P01587; Ala18-Lys141). |
| Source | Monoclonal Rabbit IgG Clone #017 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-CSF Antibody; Anti-Csf2 Antibody; Anti-Csfgm Antibody; Anti-Gm-CSf Antibody; Anti-GMCSF Antibody; Anti-MGI-IGM Antibody
Background Information
| Full Name | colony stimulating factor 2 (granulocyte-macrophage) |
| Description | Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility. |
| Research Areas |
|
| Related Pathways |
|
| Tags |
|
| References |
|
